bioAffinity Technologies, Inc. 8-K
Research Summary
AI-generated summary
bioAffinity Technologies Reports Q1 2026 CyPath Lung Sales Surge
What Happened bioAffinity Technologies, Inc. (BIAF) filed a Form 8‑K on April 1, 2026 announcing that unit sales for its CyPath® Lung noninvasive lung cancer diagnostic in Q1 2026 exceeded the company's internal projections. Based on preliminary, unaudited data, the company reported 146% growth in unit sales versus Q1 2025 and cited accelerating physician adoption and expanding clinical use. The company attached a press release (Exhibit 99.1) to the filing.
Key Details
- Filing date: April 1, 2026 (Form 8‑K, Item 8.01 Other Events).
- Reported metric: Q1 2026 unit sales for CyPath® Lung increased 146% vs. Q1 2025 (preliminary, unaudited).
- Company statement attributes growth to accelerating physician adoption and expanding clinical use.
- Press release announcing the results is included as Exhibit 99.1 to the 8‑K.
Why It Matters This disclosure signals meaningful commercial traction for bioAffinity’s CyPath® Lung test, showing strong year‑over‑year unit growth early in 2026. For investors, the 146% increase (preliminary) may indicate improving market acceptance and potential revenue momentum, though the filing notes the figures are unaudited and preliminary. The press release attached to the 8‑K is the company’s official announcement of these results.